Navigation Links
Seahorse Bioscience, Inc. Appoints In Vitro Technologies Pty Ltd as New Distributor in Australia and New Zealand
Date:3/2/2011

NORTH BILLERICA, Mass., March 2, 2011 /PRNewswire/ -- Seahorse Bioscience, Inc., the leader in the design and development of instruments for assessing cellular bioenergetics, has announced In Vitro Technologies Pty Ltd as the new distributor of Seahorse XF Analyzers and consumables in Australia and New Zealand.

Seahorse Extracellular Flux Analyzers provide the first and only kinetic method to measure the two major energy producing pathways - mitochondrial respiration and glycolysis - in living cells in a microplate.

"In Vitro's Life Science product portfolio represents the highest quality laboratory instrumentation, equipment and consumables from around the world. With the interest in cellular bioenergetics in the Australia region the Seahorse brand is a perfect fit in our distribution strategy to focus on in vitro cell research," said Jennifer Parsons, Managing Director of In Vitro Technologies.

Seahorse XF Analyzers enable scientists to assess the impact of drugs, genetic modifications and environment by monitoring the rate that cells consume oxygen and produce metabolic byproducts.

"Our goal was to partner with a distributor who provides quality sales, service and support to customers in the cell based assay market," noted Steve Chomicz, VP Sales and Marketing for Seahorse. "The partnership with In Vitro will allow us to accelerate our sales as they have existing relationships with our ideal customer base."

About In Vitro Technologies Pty Ltd

In Vitro Technologies, founded in 2002, is a privately owned Scientific and Medical distribution company specializing in the sale and support of scientific, clinical diagnostic, medical and related products. The company is owned by JJ Richards & Sons Pty Ltd, one of Australia's largest employers with over 1,200 employees and revenues in excess of $300 million.

For more information, please visit http://www.invitro.com.au

About Seahorse Bioscience

Seahorse XF instruments have become the new standard in cellular bioenergetic measurements. Scientists worldwide are advancing their research in understanding the role of cellular bioenergetics in Aging, Cancer, Cardiovascular, Cell Physiology, Toxicology & Hepatobiology, Immunology, Infectious Diseases, Mitochondrial Diseases, Model Organisms, Neurodegeneration, Obesity, Diabetes, & Metabolic Disorders, Screening, and Translational Medicine. Seahorse is headquartered in Billerica, Massachusetts US.

For more information, please visit http://www.seahorsebio.com

Contact:  Cynthia Egan, Seahorse Bioscience, Inc., 1-978-671-1600, cegan@seahorsebio.com


'/>"/>
SOURCE Seahorse Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
2. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
3. Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference
4. TheScientist Awards Seahorse XF96 Analyzer a Top Ten Innovation for 2009
5. Seahorse Bioscience to Present at 2010 UBS Global Life Sciences Conference
6. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
7. Omeros Appoints David A. Mann to its Board of Directors
8. RainDance Technologies Appoints Olex Vice President, System Development
9. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
10. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
11. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... NX Prenatal Inc., a US based ... for early warning of adverse pregnancy outcomes, announced ... by Dr. Thomas McElrath of Brigham ... Medicine,s (SMFM) annual meeting held in ... The presentation reported initial positive top-line results regarding ...
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... ... 2016 , ... Benchmark Research, a fully-integrated network of ... principal investigators (PI) to the roles of Chief Medical Officer, Clinical Research and ... Chu, a Benchmark Research PI in the Austin office, will assume the role ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC ... support program, Sonalinkā„¢ remote monitoring. The inaugural launch of this new technology occurred ... connecting Dr. Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
Breaking Biology News(10 mins):